Medicine
Estrogens, conjugated 0.9 mg tablet
Estrogens, conjugated 0.9 mg tablet is a generic prescription medicine for oral use, made by 2 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59°…
Key facts
- Active ingredient (INN)
- Estrogens, conjugated
- Brand
- Sold under the generic name
- Strength
- 0.9 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 100 tablets, 1000 tablets
- Manufacturers
- Ingenus PharmaceuticalsPrasco Laboratories
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- G03CA57 Estrogens, conjugated
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 16 October 2025
- Identifiers
- RxCUI 197660, 197661, 197662 +2DailyMed set ID ce793f9e-0c20-43e6-9dc0-064e5c82e243, 7277bab4-d8c2-4e4b-a0d9-5dfe1885d547NDC 66993-298, 50742-390Application NDA004782, ANDA214023
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, film coated in 1 bottle | 50742-390-01 | Ingenus Pharmaceuticals | 16 October 2025 |
| 1000 tablet, film coated in 1 bottle | 50742-390-10 | Ingenus Pharmaceuticals | 16 October 2025 |
| 100 tablet, film coated in 1 bottle | 66993-298-02 | Prasco Laboratories | 27 February 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 8 May 1942 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Estrogens, conjugated 0.9 mg tablet.
Other strengths and forms of Estrogens, conjugated
Clinical summary
Estrogens, conjugated is an estrogen indicated for treatment of Moderate to Severe Vasomotor Symptoms due to Menopause, among other approved uses. MedsAcross supplies Estrogens, conjugated for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Estrogens, conjugatedFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Premarin prescribing information (Wyeth Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Estrogens, conjugated 0.9 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.